Arix today announces the following updates to its Board and Executive team

LONDON, 6 October 2021: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the following updates to its Board and Executive team:

  • Following six months as interim CEO, Robert Lyne has been appointed permanent Chief Executive Officer, effective immediately.
  • Sir Michael Bunbury will join the Board as Senior Independent Director, effective today.
  • Giles Kerr, Non-Executive Director and Chair of the Board’s Audit Committee, will step down from the Board on 15 October 2021, after four years of service.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH